Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Infectious meningitis and encephalitis in adults in Denmark: A prospective nationwide observational cohort study (DASGIB)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Would you like to purchase a rodent with dermatophytes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pediatric Candidemia Epidemiology and Morbidities: A Nationwide Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus isolates from 2012 to 2014 with voriconazole as comparator.

METHODS: Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs) (where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC50). The CYP51A gene was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were determined for selected Aspergillus isolates with isavuconazole MIC ≥2 mg/L.

RESULTS: Isavuconazole MIC50(range) (mg/L) against Candida species were: Candida albicans: ≤0.03 (≤0.03 to >4), Candida dubliniensis: ≤0.03 (≤0.03), Candida glabrata: ≤0.03 (≤0.03-4), Candida krusei: 0.06 (≤0.03-0.5), Candida parapsilosis: ≤0.03 (≤0.03-0.06), Candida tropicalis: ≤0.03 (≤0.03 to >4), Saccharomyces cerevisiae (anamorph: Candida robusta): ≤0.03 (≤0.03-0.5). Non-wt isavuconazole/voriconazole MICs were found for C. albicans: 0.8/1.0%, C. dubliniensis: 0/1.8%, C. glabrata: 14.9/9.5%, C. krusei: 2.7/1.4%, C. parapsilosis: 1.7/1.8%, C. tropicalis: 14.3/19.1% and S. cerevisiae: 10.0/0%. Isavuconazole MIC50(range) (mg/L) against Aspergillus species were: A. fumigatus: 1 (≤0.125 to >16), Aspergillus niger: 2 (1-8), Aspergillus terreus: 1 (0.25-8), Aspergillus flavus: 1 (0.5-2), Aspergillus nidulans: ≤0.125 (≤0.125-0.25). Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus, 4.9/0% A. niger and 48.2/22.2% A. terreus.

CONCLUSION: Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of C. glabrata, C. tropicalis and A. fumigatus isolates were non-wt, reflecting increased resistance at a reference centre and technical issues. Significant CYP51A alterations were reliably detected applying the isavuconazole breakpoint.

Original languageEnglish
JournalClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Volume23
Issue number11
Pages (from-to)882-887
Number of pages6
ISSN1198-743X
DOIs
Publication statusPublished - Nov 2017

    Research areas

  • Journal Article

ID: 52705167